Skip to content

Mechanical Cough Augmentation in Children With NMD

Prevalence and Use of Mechanical Cough Augmentation in Children With Neuromuscular Disorders in Norway

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03831568
Enrollment
72
Registered
2019-02-06
Start date
2018-01-01
Completion date
2019-01-31
Last updated
2019-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Clearance Impairment, Children, Only, Cough, Neuromuscular Diseases

Keywords

Airway management, Cough, Neuromuscular diseases, Pediatrics, Mechanical insufflation-exsufflation

Brief summary

The study investigates the prevalence and use of mechanical insufflation - exsufflation (MI-E) in children with Neuromuscular disorders (NMD) in Norway. The NMD related prevalence of MIE use in Norway will be described and possible regional differences regarding use will be assessed.

Detailed description

Neuromuscular diseases (NMD) in children are severe, possibly life-threatening orphan conditions. Respiratory tract infections and lung complications are the main causes of increased morbidity and mortality. The use of mechanical cough augmentation with insufflation-exsufflation (MIE) is a strategy to treat and prevent. Possible major benefits are described, but optimal settings for best efficacy and comfort in children are not established. The main objective is to determine the prevalence and use of MIE among children with NMD in Norway. All children with NMD \< 18 years which has received a machine for MI-E will be invited to participate in the study. The participants will be asked to complete two questionnaires. In addition will information from the data card in the MI-E machines give information about use. The information will be linked to the National register for Long term mechanical ventilation.

Interventions

None listed

Sponsors

University Hospital of North Norway
CollaboratorOTHER
St. Olavs Hospital
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
Helse Stavanger HF
CollaboratorOTHER_GOV
Sorlandet Hospital HF
CollaboratorOTHER_GOV
Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

, * Received a MI-E device * Neuromuscular disease * \< 18 years

Exclusion criteria

\- None

Design outcomes

Primary

MeasureTime frameDescription
ResidencyAt one point (1 day)Name of county
Indication for useAt one point (1 day)Prevention or treatment purposes from questionnaire
Diagnosis01.01.2018International Classification of Diseases - 10 diagnosis

Secondary

MeasureTime frameDescription
Health related quality of lifeOne time at completion of questionaireThe DISABKIDS Chronic Generic Module (DCGM-37) is a questionnaire measuring general health-related quality of life (HRQoL) and the level of distress caused by a chronic disease at 3 domains (mental, social and physical) in 6 dimensions: Independence, Emotion, Social inclusion, Social exclusion, Limitation and Treatment. Each item is scored on a five-point Likert scale which indicates behavior or feelings as 1 = never, 2 = seldom, 3 = quite often, 4 = very often and 5 = always. There is one form to be filled in by children 8 to 18 years of age, and one form by their parents. The sum of scores within each dimension makes up the raw score, which is transformed linearly into a score ranging from 0 to 100. The scores are added and further transformed into a total HRQOL score with a range 0 to 100 with higher scores indicating higher HRQOL.
Settings in useOne time at completion of questionaireRecorded from data card in MIE machine
Opinion on treatmentOne time at completion of questionaireA purpose made questionnaire including questions with predefined categorical data in no order, and 2 questions using a Visual Analog Scale 0-10 to score perceived benefit of the treatment where 0 indicates not important at all and 10 indicates very important.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026